Arcus Biosciences reported more than $400 million in cash and equivalents at December 31, 2025, following R&D and operating expenditures during the quarter. Company executives emphasized that this strong cash balance funds operations through key Phase II data readouts in the first half of 2026 and noted active discussions with potential partners to expand clinical development and mitigate burn rate.